MSB

3.21%

$1.13 mesoblast limited

Why a trial?, page-28

First 28 Last

Share
Profile

Follow
dachopper

4,194 Posts.

5493

10/08/23

01:28

Post #: 69258201
Share

Originally posted by Southoz: ↑

Simple rule of thumb is the more innocuous the contents of a CRL the happier companies will be to share the details.

Here we have two words – “more data”.

So the working assumption is that the FDA were completely unconvinced by the resubmission and have not budged one inch from their “at least one additional randomised controlled trial” position.

There is a slight possibility this might not be true.

In the first CRL MSB went straight to appeal; this had the effect of finalising the CRL.

In CRL2 MSB are heading to a Type A meeting. And so they can argue the process is still in progress; a incomplete negotiation. So with backwards and forwards still to come what is in the CRL today may not be there tomorrow.

Bear in mind that a CRL itself is a summary. A few pages summarising what will be hundreds / thousands lines of emails / discussions etc within the FDA. And so MSB might not have a good understanding around the FDA thinking behind some issues or how strongly their positions are held.

But realistically I don’t think anything now can change the path that gvhd is on. Which is heading to Gods waiting room. An academic network will be tasked with doing some design work and identifying opportunities for funding. In a couple of years only the old timers here will remember anything about it.

For now there is far more pressing issue of funding. If people recall a week or so ago I did a simple back of envelope risk reward calculation to get a handle on the market odds for probability of approval. I used an estimated downside share price of 80c in the case of rejection. Given a share price of around 110c my prognostication was the rejection would be a anti climax because the market was already pricing in failure.

This will make the top 5 of my silliest HC predictions.

I was completely oblivious to the financial consequences from the CRL. This was because finance is not my area of interest, I have no skills in it and consequently I never bother about it. Big mistake because the here the two – the clinical and finance were interlinked.

So that is one big lesson I have learned. Don’t forget that a biotech with complex opaque financial arrangements is a house of cards that may not be very resilient to a few puffs of wind from the FDA.

But from this perhaps flows the only glimmer of positivity I can see for MSB. We can debate SI’s skillset but no-one doubts his fund raising abilities. So SI might be the man for moment to put out this dumpster fire in a train wreck; which admittedly is of his own making.

Expand

In the big scheme of things, the company is bringing in 11 million a year in royalties and climbing, market value under 300 million.

Back pain phase 3 product that reduces back pain
CHF phase 3 product that reduces 3 point mace, overall survival, non fatal heart attack and strokes
GvHD phase 3 product that reduces mortality
Crohns phase 1/2 product that had 4 patients all in remission

Yes - usually FDA need 1 more trial. So thats' what MSB should do.

Forget the share price, the cells work. Get the cash, partner up and get going !

With 70 million in the bank, and plenty of funding options, not as grim as people think

MSB Price at posting: 35.0¢ Sentiment: Buy Disclosure: Held
38 Upvote

10 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The market's shrugged at China's stimulus measures all year. Why is this one different?

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

There are more pages in this discussion • 80 more messages in this thread...

First 28 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.13		Change 0.035(3.21%)		Mkt cap ! $1.284B

Open	High	Low	Value	Volume
$1.09	$1.13	$1.07	$3.910M	3.535M

Buyers (Bids)

No.	Vol.	Price($)
2	27197	$1.11

Sellers (Offers)

Price($)	Vol.	No.
$1.13	43578	3

View Market Depth

No.	Vol.	Price($)
4	31763	1.100
2	33264	1.090
2	18897	1.085
2	18926	1.080
1	18000	1.075

Price($)	Vol.	No.
1.130	23400	3
1.135	1090	1
1.140	65000	4
1.145	64500	3
1.150	92314	9

Last trade - 16.10pm 27/09/2024 (20 minute delay)

MSB (ASX) Chart

Why a trial?, page-28

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The market's shrugged at China's stimulus measures all year. Why is this one different?

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Why a trial?, page-28

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The market's shrugged at China's stimulus measures all year. Why is this one different?

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News